CELB ACE™ System : Cancer is the number one cause of death. It is estimated that 1 in 3 people develop cancer. The most important way to reduce cancer deaths is “early cancer screening.” However, invasive cancer diagnosis causes patient pain, concerns about complications, and is expensive. For early cancer diagnosis, it is important to extract cancer cell-derived nucleic acid (ctDNA) and circulating tumor cells (CTC), but separation is not easy due to PBMC and protein components in the blood. To overcome these difficulties, the CELB ACE™ System is a liquid biopsy in vitro diagnostic medical device that can extract ctDNA from the blood of cancer patients and isolate circulating cancer cells.

CELB ACE™ System is an in vitro diagnostic device [1], which can rapidly extract and purify ctDNA and CTC from liquid samples(plasma, serum and urine) and PBMC(peripheral blood mononuclear cell), respectively. Isolated high-quality ctDNA and CTC are suitable for PCR, ddPCR, Genotyping, NGS, and Immunostaining.

[Application]

• Early Cancer Diagnosis : ctDNA methylation with NGS

• Provides Evidence for Predicting Tumor Metastasis & Anti-Cancer Therapeutic Effects : CTC enumeration

• Personalized / Companion Diagnosis for Cancer Therapy : Cultivation of Isolated CTC

• Tumor Metastasis Research & New Drug Development : Single Cell Analysis of CTC